Singapore's leading national tertiary cancer centre, National Cancer Centre Singapore, has announced a new S$6 million ($4.7 million) collaboration to develop an AI-powered cancer test that uses advanced genomic sequencing to provide clinicians a more complete view of tumours and guide treatment decisions.
It partnered with precision oncology company Lucence and the Diagnostics Development Hub (DxD Hub) of the Agency for Science, Technology and Research, Singapore (A*STAR) for the UNITED 2.0 project.
The NCCS explained that a more detailed tumour profiling – including the identification of complex mutations and fusions – helps clinicians identify genetic alterations that can be targeted with precision treatments.
According to NCCS, the upgraded clinical-grade cancer profiling test will analyse a broad range of cancers, including breast, lung, colon, bladder, central nervous system tumours, and lymphoma.
The three-year collaboration also plans to develop tools to monitor a patient's status after treatment, including Minimal Residual Disease (MRD) testing to detect early signs of cancer recurrence.
【MORE】